MOONLAKE IMMUNO (MLTX)
(Delayed Data from NSDQ)
$51.04 USD
+4.62 (9.95%)
Updated Sep 12, 2024 03:59 PM ET
After-Market: $51.02 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
MLTX 51.04 +4.62(9.95%)
Will MLTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MLTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MLTX
Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
MLTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%
Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates
MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for MLTX
MoonLake Immunotherapeutics: A Strong Buy on Promising Sonelokimab Trials and Market Potential
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
Boeing's Starliner to return without astronauts: Morning Buzz
Kymera upgraded, MoonLake downgraded: Wall Street's top analyst calls
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts